This study aimed to estimate the current prevalence and treatment cost of noncommunicable diseases attributed to tobacco in the Indonesian population in 2015. An epidemiological study was performed. Using the national universal coverage database, we calculated the morbidity and treatment cost of 19 diseases. Proportion of smoking-attributed diseases and treatment costs because of smoking were calculated using smoking-attributable fraction. The study revealed that the morbidity of smoking-related diseases accounted for 991 331 cases, about 21.6% of total cases of chronic diseases in Indonesia. The highest incidences of disease were hypertension, chronic obstructive pulmonary diseases, and ischemic heart disease. The treatment cost of smoking in Indonesia was conservatively estimated to be at least US$2177 million, approximately 2.5% of the 2015 gross domestic product. A majority of the cost was largely concentrated in the male population (US$2164 million). Treatment costs of hypertension, chronic obstructive pulmonary diseases, and ischemic heart disease had the highest cost burden. This study's findings provide scientific evidence about the economic burden of smoking, particularly the health care expenditure covered by the government. This study's evidence is important for informing national public health policy to advocate the health promotion and prevention program.
Introduction
There is robust evidence on the negative impacts of tobacco smoking on individuals' health. Studies have shown that smoking directly causes or increases the risk of several diseases, including cardiovascular diseases, 1 respiratory diseases, 2 and various types of cancer. 3 Nonsmokers are also subjected to heightened risks of these diseases because of secondhand smoke. From a global perspective, tobacco kills more than 7 million people a year. More than 6 million of those deaths are the result of direct tobacco use, while around 890 000 are the result of nonsmokers being exposed to secondhand smoke. 4 To reduce mortality of chronic diseases, implementing universal coverage especially in lower middle-income countries like Indonesia must be encouraged. 5 Currently, chronic diseases, including diabetes, cardiovascular diseases, and cancers, are major concerns of public health in Indonesia because of the high cost of treatment and substantial burden to the national budget since universal coverage has been applied in 2014. 6 In fact, Indonesian smokers is highest among the ASEAN countries, 7 and the country recently dis not ratify the World Health Organization Framework Convention on Tobacco Control, and there are no restriction legislations to protect nonsmokers. 8 Smoking prevalence is currently relatively high, about 32% in 2013 (67% for males, 2.1% for females). 9 A large part of this may be attributed to its non-commitment to the World Health Organization Framework Convention on Tobacco Control. 8 Several preventive measures have been identified that provide the most feasible approach to mitigate the global increase in noncommunicable diseases (NCDs) in developing countries. Foremost among these are the need to strengthen efforts in tobacco control. 10 Presenting data on the impacts of smoking as monetary values is important to advocate the government in implementing national tobacco control initiatives. An important indicator developed by the World Health Organization is the Economics of Tobacco Toolkit on the assessment of the economic costs of smoking. 11 Focusing on prevalence data, this includes smoking-attributable fractions, prevalence rate, and smoking-attributable treatment costs (SATCs). Burden of cancer is considered very crucial in economics, 12 and measuring the treatment costs of diseases related to smoking is very important for countries where the prevalence of smoking is high.
In Indonesia, for the first time, an economic cost study has been conducted in 2008, and the study showed that there were 602 350 deaths due to diseases attributed to smoking, or almost one third of the estimated total deaths in the same year; the study also showed DALY (disabilityadjusted life year) loss of 13 066 230, or 25.5% of total DALYs, in the same year, and at the macro-level, the DALY loss caused an economic loss of US$18.5 billion. 13 In our study, a first attempt in the Indonesia setting, an analysis of the prevalence of chronic diseases because of smoking employed updated epidemiological data and the treatment costs of chronic diseases related to smoking using payer perspectives in the Indonesian population in 2015.
Methods
In the present study, the prevalence-based, disease-specific approach was applied to estimate the chronic diseases morbidity attributed to smoking and treatment costs of chronic diseases because of smoking from the payer perspective. The 19 chronic diseases including cancers, cardiovascular diseases, and respiratory diseases were included based on availability of national data, and the smoking-attributable fraction (SAF) was used to estimate the morbidity because of smoking.
Data Sources
Smoking Prevalence. The smoking prevalence was obtained from secondary data of Basic Health Survey 2013 collected from 33 provinces and 497 districts/municipalities. Respondents consisted of 300 000 household samples. Data were collected via household interview during May to June 2013. 14 Relative Risks. The relative risks (RRs) of target cancers for smokers were obtained from published articles as described in Table 1 . 15 
Number of Cases for Each of the 19 Diseases.
Country information of adult morbidity was predicted from the BPJS (National Universal Health Coverage) database.
Calculation of Smoking-Attributable Morbidity (SAM) and SAF
Sex-and Age-Specific SAM. SAM was calculated by multiplying the total number of cases (by age 15-59, 60-80, and >80 years) for 19 diseases by the SAF of each disease.
Smoking-Attributable Fraction (SAF %).
The SAFs provide estimates of the public health burden of each risk factor and relative importance of risk factors for multifactorial diseases. 16 The diseasespecific SAFs were derived using sex-specific RR estimated from meta-analysis. 1, 2, 15, 17, 18 The SAF was calculated as 11
where "p" denotes the smoking prevalence rate and "RR" denotes the relative risk of the disease of interest.
Calculation of the Treatment Costs of Smoking
Treatment costs because of smoking were estimated by multiplying sex-and age-specific disease cases and average of treatment cost per patient in each disease.
Results
The chronic disease RRs and SAFs are shown in Table 1 . In males, lung cancer showed the greatest SAF (85%), while in females lung cancer was 12% attributable to smoking, followed by chronic obstructive pulmonary diseases (COPD; 75% and 4.8% for males and females, respectively), and coronary heart disease (66% and 4% for males and females, respectively). In all diseases the SAFs were found to be substantially higher in males than in females because the prevalence of smoking in Indonesia was higher in males than in females (67.4% male smokers and 4.5% female smokers). The estimated morbidity attributable to smoking is summarized in Table 2 . During 2015, an estimated 925 611 males and 66 719 females in Indonesia were hospitalized as a result of diseases attributable to smoking, which accounted for 21.05% of the total cases. The proportion of adult morbidity attributable to smoking was 93.27% for men and 6.93% for women, respectively, following the smoking prevalence that is higher in males. The data delineated 3 leading diseases among males attributable to smoking: hypertension (388 021), COPD (377 551), and stroke (49 061). Table 3 shows SATCs of 19 diseases in 2015. In estimates for year 2015, SATC was approximately US$2177 million, which consisted of US$2164 million for males and US$13 million for females. The 3 leading smoking-attributable diseases in terms of treatment costs were hypertension (US$1261 million), COPD (US$713 million), and ischemic heart disease (US$88 million) in both sexes combined.
Discussion
This study was the first attempt in estimating the burden of diseases attributable to smoking in Indonesia using the payer perspective. Smoking is currently a very important determinant of morbidity in the Indonesian population (991 330), accounting for 21.05% of total disease morbidity in 2015. However, the proportion of disease prevalence caused by smoking exhibited large variations among different sexes (for men 93.27% of total disease morbidity and for women 6.73% of total disease morbidity). In addition, the number of smoking-attributable disease varies according to trend in the number of cases from each disease itself.
The different pattern in the variety of diseases incidence was captured in this study when compared with other countries. The differences occur because the shape and maturity of the smoking epidemic is highly affected by region-specific socioeconomic and cultural determinants of smoking, as well as because background mortality varies across populations.
It predicts that the smoking-attributable disease incidence will remain high and relatively unchanged, primarily because of increase in population size (particularly among older age groups). At present, the cohort of smokers with highest peak prevalence has still not reached the ages with highest incidence of smoking-attributable diseases, especially in cancer and others NCDs; therefore, the highest prevalence of these cases will occur in the next 20 to 30 years. Currently, NCDs account for 63% of total deaths in Indonesia. 19 In the case of Indonesia, cardiovascular diseases are the largest contributors toward NCD mortality. Hence, the country is still clearly grappling with a double burden of the disease. Given that health spending in Indonesia is a mere 2.8% of gross domestic product, its public health spending is quite low compared with other countries' health expenditures, such as Thailand (4.1%) and Malaysia (4.2%). 20 Compared with the earlier estimations on SAFs in Indonesia, 13 this study represents a major improvement in 2 ways. First, the RR of current smokers versus nonsmokers was provided by recently published articles that provided comprehensive smoking exposure and mortality data. Second, the prevalence rate of smoking among males and females came from the current Basic Health Survey database. These data represented 95% of the total population. Therefore, the current estimation of SAFs was more precise. SAFs are highest for lung cancers, larynx cancer, and mouth and oropharynx cancer; however, because the absolute number of cases were highest for lung cancer, mouth and oropharynx cancer, and liver cancer, it contributes to higher SAM.
Direct costs presented by health care cost show that total treatment cost accounted for an estimated US$2177 million. Most SATCs were related to hypertension, COPD, and ischemic heart disease. The huge treatment cost toward diseases attributable to smoking places a substantial burden on the government in Indonesia.
The results of the present study were in line with previous studies, which showed that cancers because of smoking cost the Indonesian economy an estimated US$1309 million in 2013 in terms of premature mortality costs. 9 Because of higher prevalence of smoking in males, it is not surprising that the male group accounted for much of the cost. A similar pattern was found in Hong Kong 21 and Iran, 22 wherein costs due to cancer were higher in males than in females. This study confirms that the highest prevalence of smoking in Indonesia among ASEAN countries imposes a substantial economic burden as well as a considerable public health impact.
The findings in this article are subject to limitations. First, the estimates understate disease cases attributable to tobacco use because we did not take into account former smokers as well as secondhand smokers in Indonesia, who are substantially high in number. We also did not include the cost from a societal perspective in this study, which implied underestimated findings. Estimates of disease incidence attributable to pipe smoking and smokeless tobacco use were also unavailable. Second, RRs were based on published studies in the developed world, which might have had different smoking histories, such as age of initiation and duration of smoking before quitting, rather than current or former smokers. Uncertainty nonetheless remains, especially in Indonesia, where both complete mortality records and detailed studies of disease risk factors are less common. Therefore, comparing the results from previous studies that used similar approaches to quantify the economic impacts of smoking is needed. Moreover, health care costs understate the total costs of chronic diseases because of smoking as costs associated with disease-related disability were not included.
In conclusion, cigarette smoking continues to impose substantial health and financial costs on the society. The prevalence-based, disease-specific analysis described here shows clearly that the health and economic impact of NCDs attributed to smoking in Indonesia are very dramatic and should be reduced by implementing smoking cessation and related tobacco control policies in order to reduce the high prevalence of smoking in Indonesia.
